Latest Articles
SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma：A Case Report - Frontiers
SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma：A Case Report Frontiers
Published: Feb. 10, 2025, 2:08 p.m.
The Role of Innovation in Women’s Primary Care - Femtech Insider
The Role of Innovation in Women’s Primary Care Femtech Insider
Published: Jan. 29, 2025, 8:51 p.m.
More reproductive health training needed for primary care nurses, says report - Nursing in Practice
More reproductive health training needed for primary care nurses, says report Nursing in Practice
Published: Dec. 12, 2024, 11:59 a.m.
Primary Umbilical Endometriosis (Villar’s Nodule): A Case Report - Dove Medical Press
Primary Umbilical Endometriosis (Villar’s Nodule): A Case Report Dove Medical Press
Published: Dec. 11, 2024, 7:09 a.m.
Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study - Nature.com
Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study Nature.com
Published: Oct. 19, 2024, 7:34 p.m.
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!